2018-11-22
8 reasons why china is the most exciting healtcare story in the world right now.(PART-ONE)
为什么中国现在是世界上最令人兴奋的医疗保健故事的8个原因
Franck Le Deu:Senior Partner McKinsey &Company,Head of Greater China Health care practice.
弗兰克乐迪:麦肯锡公司高级合伙人大中华健康中心总裁。
I have had the privilege(特权、优惠、权限) of living in china for well overa decade.The healthcare market has changed dramatically(显著地、戏剧的) during this time,and it has never been a dull (枯燥、平淡)experience to follow its development .I have come to the conclusion,though,that the China market has never been more exciting than it is today.Here are 8 reasons why.
我很荣幸在中国生活了数十年,在此期间医疗保健市场发生了戏剧性的变化,并且跟随它的发展这从来都不是枯燥的经历。然而,我从中得到了这样的结论,中国的市场直至今日从未这么令人激动过。这里有八个为什么的原因。
1. The potential(潜在的、潜力) for patient(患者、耐心) and economic impact(撞击、影响) is gigantic(巨大的、不可思议的)
潜在的患者和经济影响是巨大的
Health China 2030,China’s national healthcare strategy(战略、策略) published in 2016,has set(设置、集合、规定的) ambitious(雄心勃勃的) targets(目标、投放范围) for improving health outcomes(结果、产出) for the Chinese population .Progress(进步、进展) has already been made.For example,life expectancy(期望、期待) of Chinese women and men has improved from 68 to 77 in the last 30 years.
在2016年,中国国民健康医疗战略发布了《健康中国2030》,基于中国人口,为了提高健康结果已经规定了雄心勃勃的目标,并且进展已经取得进展。比如说:在近三十年中国男性和女性的平均寿命已经从68岁提升至77岁.
But so much more can be done,especially in the context of (在..情况背景下)a rapidly(迅速的、急速) aging society(老龄化社会).By 2030,the hope of the Chinese goverment is to create a 16 trillion(兆、万亿) RMB broader(宽广的、拓宽) healthcare ecosystem(生态系统) by continuously(连续、多次) strengthening(加强) preventative(预防(性的)) care,optimizing(最佳化、优化) healthcare management(管理(学)、经营) and services,and taking care of key segments(关键环节)of the population,such as women and children.Taken together,these initiatives(举措、方案) couldtranslate into billions of(数以亿计的) additional(附加、额外) life years,and will have an enormous(巨大的) impact on productivity(生产力) and economic development in China.
但是还有很多事情可以做,尤其实在急速老龄化的背景下。在2030,中国政府希望创造16万亿人民币拓宽医疗保健生态系统通过连续加强预防性管理、优化医疗保健管理和服务,并且照顾人口的关键环节,比如女性和儿童。合在一起,这些举措可以被转化为数以亿计的附加生活年限,并且还会在生产力和经济发展上产生巨大的影响。
2. Chinese labs are starting to crank out innovation
中国的实验室开始加速创新
The signs(标志/苗头) are all here : A wave of ‘sea turtles’ returning to China to seek their fortunes(命运/财富) , abundant (丰富的)sources(资金) of funding . direct(直接支援)support by central and local goverment , unprecedented(空前) speed of decision-makingand execution(执行) by regulators(监管者/部门) , and a degree of (..的程度/学位)freedom to operate(操作/纵) not always seen even in the West .
所有的苗头都在这里:一波海龟返回中国寻找他们的财富,由中央和当地政府提供丰富的资金直接支援,通过监管部门空前做决定和执行的速度,并且在一定程度上自由操控即便在西方都不怎么常见。
These are all feeding a rapidly(立即/迅速的) expanding petri dish(培养皿)of innovation(创新/革命) that is starting to yield(屈服/让位/生息) tangible(实在的/有形资产) scientific outcomes. New molecules(分子/学) for lung cancer(fruquintinib(呋噬替尼) discovered by Chi-Med),CAR-T,PD-1,are just a few(一些/几个)concrete(混泥土/具体的) examples.Beyond these cases,there’s the emergence(出现/浮现) of innovative(创新的) MedTech医疗技术 companies ( e-g:Venus MedTech in minimally(最低程度的) invasive(侵略/侵害) heart nalves(心脏瓣膜)),next generation sequencing(测序/排序/定序) companies(e.g:Berry Genorics) , or big date companies (e-g: LinkDoc , focused on oncology(肿瘤学) and already valued at(将..估价为)$1Billion , four years after it was started) . Just a few years ago , development such as these would have been unthinkable .
这些正在孕育一个迅速扩大的创新培养皿,并且这个培养皿已经开始产生实实在在的科学性成果。肺癌的新分子(呋噬替尼被迟木德发现)CAR-T,PD-1,只是一些几个具体的例子。除了这些案例,这里还出现了创新医疗技术的公司(如:最低程度侵害心脏瓣膜的维纳斯医疗技术公司,下一代测序公司(如Berry Genorics,或者大数据公司(如:LinkDoc,专注于肿瘤学并且在成立四年后已经被估价值10亿美元)。就在几年以前,这样的发展是不可思议的。
3. Fast and furious reform at the CFDA/NMPA
CFDA/NMPA的速度与激情改革
It’s fair to say that reform(改革/发动) initiated(开始/发动) in late 2015 by the CFDA, now under NMPA,has been broader,deeper,and has moved faster than anyone could have anticipated(预料/期望).My Mckinsey colleagues(同行/同事) across sector(扇形/部门/行业类别),would agree that this is largely(主要的/大部分/很大程度上) unmatched(独步/无与伦比) by other sectors in china.The degree to which innovations(创新) that originate(首创/起源) in china are beingintegrated into(纳入/集成到)global drug trials and launches(汽艇/发射) is unprecedented (史无前例的/空前), and the success rate is tangible(实在的/具体的),with around 100 new drugs approved since 2016,setting a new record.
公平的说,2015年下旬由国家食品药品监督管理局发动的改革比任何人预想的都要广泛、深入、迅速。我在麦肯锡的同行横穿各个部门,并且他们都赞同在中国这在很大程度上较其他行业它都是无与伦比的。来自中国的创新被整合到全球药物实验和发布中的程度是前所未有的,而且成功率是实实在在的,自2016年以来大约有100种新药获得批准,创造了新的记录。
来自LinkedInAchievements also include the publication of a rare disease list,creation of a fast track mechanism(机制/机构学),acceptance (接受/承兑/验收)of foreign(外籍/中外) date for registration,and the definition of a conditional(有条件的/假定的) approval pathway:”any news from the NMPA is positive.”Some multinationals(跨国公司) have seen their new drug candidates(候选人/应征人员/申请者) attain(达到/获得/完成) such swift(迅速的) approval they’ve had to scramble(争抢/攀登) to get them to market.
工作成就也包括罕见疾病名单的发布,创造了快速通道机制,接收中外数据的登记,以及有条件批准途径的定义:“任何来自NMPA的消息都是积极地。”一些跨国公司看到他们的新药得到如此快速的批准,他们不得不争先恐后的将它们推向市场。
---未完待续
TO BE CONTINUDE